Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208767 · ClinicalTrials.gov registry record · Phase 2
Effect of Valsartan on Carotid Artery Disease
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00208767 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 120 participants.
The verdict
NCT00208767, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The EFFERVESCENT trial is designed to evaluate the effects of a specific ARB, called valsartan, on atherosclerosis. The investigators want to know if treatment with valsartan will increase the blood levels of markers responsible for repair of the vessel wall, reduce oxidation and inflammation, improve the function of the blood vessels, and arrest or slow down the progression of atherosclerosis over time.
Interventions
- DRUG Placebo
- DRUG Valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-02 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208767
The ClinicalTrials.gov registry entry for NCT00208767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00208767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00208767 about?
NCT00208767 is a clinical study titled "Effect of Valsartan on Carotid Artery Disease". The EFFERVESCENT trial is designed to evaluate the effects of a specific ARB, called valsartan, on atherosclerosis. The investigators want to know if treatment with valsartan will increase the blood levels of markers responsible for repair of the vessel wall, reduce oxidation and inflammation, impro...
What is the current status of trial NCT00208767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2005-02. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00208767?
The interventions under investigation include: Placebo (DRUG), Valsartan (DRUG).
Who is sponsoring clinical trial NCT00208767?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.